Identification of a novel MET mutation in high-grade glioma resulting in an auto-active intracellular protein

Intracellular and extracellular domains of protein tyrosine phosphatase PTPRZ-B differentially regulate glioma cell growth and motility

(2015) Annika M. Bourgonje et al.   Oncotarget

Regulation of HGF Expression by ΔEGFR-Mediated c-Met Activation in Glioblastoma Cells

(2015) Jeannine Garnett et al.   NEOPLASIA

"Companion Diagnostics": Has Their Time Come and Gone?

(2014) F. R. Hirsch et al.   CLINICAL CANCER RESEARCH

Comprehensive molecular profiling of lung adenocarcinoma

(2014) Eric A. Collisson et al.   NATURE

Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors

(2014) Elizabeth Smyth et al.   OncoTargets and Therapy

Targeting hepatocyte growth factor receptor (Met) positive tumor cells using internalizing nanobody-decorated albumin nanoparticles

(2013) Raimond Heukers et al.   BIOMATERIALS

Novel Oncogenic PDGFRA Mutations in Pediatric High-Grade Gliomas

(2013) B. S. Paugh et al.   CANCER RESEARCH

Analysis ofEGFR,EML4-ALK,KRAS, andc-METmutations in Chinese lung adenocarcinoma patients

(2013) Ning Xia et al.   EXPERIMENTAL LUNG RESEARCH

The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered

(2013) Hui K. Gan et al.   FEBS Journal

Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

(2013) David R. Spigel et al.   JOURNAL OF CLINICAL ONCOLOGY

EGFR wild type antagonizes EGFRvIII-mediated activation of Met in glioblastoma

(2013) L Li et al.   ONCOGENE

Effects of Dual Targeting of Tumor Cells and Stroma in Human Glioblastoma Xenografts with a Tyrosine Kinase Inhibitor against c-MET and VEGFR2

(2013) Anna C. Navis et al.   PLoS One

Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics

(2013) A. Sottoriva et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cell-Autonomous and Non-Cell-Autonomous Mechanisms of HGF/MET-Driven Resistance to Targeted Therapies: From Basic Research to a Clinical Perspective

(2013) S. Corso et al.   Cancer Discovery

Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer

(2013) Alberto Bardelli et al.   Cancer Discovery

VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex

(2012) Kan V. Lu et al.   CANCER CELL

A combined oncogenic pathway signature ofBRAF,KRASandPI3KCAmutation improves colorectal cancer classification and cetuximab treatment prediction

(2012) Sun Tian et al.   GUT

Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma

(2012) Toni K. Choueiri et al.   JOURNAL OF CLINICAL ONCOLOGY

EGFR and KRAS mutations and altered c-Met gene copy numbers in primary non-small cell lung cancer and associated stage N2 lymph node-metastasis

(2011) Cheng-Bo Han et al.   CANCER LETTERS

Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification

(2011) Sai-Hong Ignatius Ou et al.   Journal of Thoracic Oncology

A direct role for Met endocytosis in tumorigenesis

(2011) Carine Joffre et al.   NATURE CELL BIOLOGY

Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion

(2010) Yoshinari Asaoka et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

(2010) Roel G.W. Verhaak et al.   CANCER CELL

PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas

(2010) T. Ozawa et al.   GENES & DEVELOPMENT

Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers

(2010) Ryoichi Onozato et al.   Journal of Thoracic Oncology

Deletion or insertion in the first immunoglobulin-plexin-transcription (IPT) domain differentially regulates expression and tumorigenic activities of RON receptor Tyrosine Kinase

(2010) Qi Ma et al.   Molecular Cancer

EGFRvIII Deletion Mutations in Pediatric High-Grade Glioma and Response to Targeted Therapy in Pediatric Glioma Cell Lines

(2009) D. A. Bax et al.   CLINICAL CANCER RESEARCH

Phenotypic and Genotypic Characterization of Orthotopic Human Glioma Models and Its Relevance for the Study of Anti-glioma Therapy

(2008) An Claes et al.   BRAIN PATHOLOGY

Expression and mutational analysis ofMETin human solid cancers

(2008) Patrick C. Ma et al.   GENES CHROMOSOMES & CANCER

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

(2008) Roger McLendon et al.   NATURE